Location Directory

Clinical trials in Columbus, Ohio

This page shows live ClinicalTrials.gov search results for Columbus, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 4:40 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

10845

Shown on this page

Current sort

Institutions in Columbus

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Ohio State University Wexner Medical Center

Live official records

Open in full search

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Obinutuzumab, Quality-of-Life Assessment, Venetoclax; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 69 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 864
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 552 more

Conditions: Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions: Biospecimen Collection, Diagnostic Imaging Testing, Doxorubicin, Echocardiography Test, Multigated Acquisition Scan, Pembrolizumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 258
States / cities: Phoenix, Arizona • Tucson, Arizona • Dublin, California + 209 more

Conditions: Metabolic Associated Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease, Cirrhosis, Liver, NASH, Liver Fibrosis, Liver Fat, Liver Steatoses, Liver Inflammation
Interventions: Not listed
Lead sponsor: Foundation for the National Institutes of Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Miami, Florida • Columbus, Ohio • Bellaire, Texas + 1 more

Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 7,458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1655
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more

Conditions: Myelodysplastic Syndrome
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Enasidenib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 147
States / cities: Berkeley, California • Irvine, California • Orange, California + 121 more

Conditions: Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Metastatic Anal Squamous Cell Carcinoma, Recurrent Anal Squamous Cell Carcinoma, Stage III Anal Cancer AJCC v8, Stage IV Anal Cancer AJCC v8, Unresectable Anal Squamous Cell Carcinoma
Interventions: Carboplatin, Nivolumab, Paclitaxel; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 579
States / cities: Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 381 more

Conditions: KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Docetaxel, Laboratory Biomarker Analysis, Trametinib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 596
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • Jonesboro, Arkansas + 375 more

Conditions: Hypertensive Disorder of Pregnancy, Preeclampsia
Interventions: Treating BP acutely with intravenous or rapid acting oral medications; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma
Interventions: Computed Tomography, Magnetic Resonance Imaging, Tazemetostat; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 581
States / cities: Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 369 more

Conditions: Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Computed Tomography, Docetaxel, Eribulin Mesylate, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Paclitaxel, Sacituzumab Govitecan; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 448
States / cities: Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 306 more

Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Echocardiography Test, Electrocardiography, Lumbar Puncture, Mesna, Methotrexate, Multigated Acquisition Scan, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 207
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 145 more

Conditions: Multiple Myeloma
Interventions: Linvoseltamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2033
U.S. locations: 14
States / cities: Miami, Florida • Tampa, Florida • Atlanta, Georgia + 10 more

Clinical trials in Columbus, Ohio

Filter and sort this location

Institutions in Columbus

Live official records

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Blood Pressure Goal in Preterm Preeclampsia

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma